Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

<h4>Background</h4>The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sa...

Full description

Bibliographic Details
Main Authors: Jose M Trigo, Alexandra Soliman, Lena C Quilty, Benedikt Fischer, Jürgen Rehm, Peter Selby, Allan J Barnes, Marilyn A Huestis, Tony P George, David L Streiner, Gregory Staios, Bernard Le Foll
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0190768